Despite Ether finally edging back toward its all-time high of $4,878, chatter on social media shows retail traders remain skeptical and in disbelief, according to Santiment.
You might also be interested in reading Exelixis outlines continued cabozantinib growth and zanzalintinib pipeline acceleration as new launches drive 19% revenue increase.